Apalutamide

阿帕他胺

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameApalutamide
Drug Alias Name阿帕鲁胺apalutamideapalutamidumapalutamidaapantamide +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAndrogen Receptor antagonists
TargetsAndrogen Receptor
Therapy Area/IndicationsCastration-Sensitive Prostate NeoplasmsHormone-Sensitive Prostate NeoplasmsHepatic Insufficiency +[9] 
Global Approved IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Approved Indications in ChinaProstatic Neoplasms, Castration-Resistant
Original Approved Country/TerritoryUnited States
Original Approved Date2018/02/14
Country/TerritoryCzechiaBelgiumCanada +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative MedicineJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Pharmaceutica SaJohnson & Johnson Innovative MedicineUniversity Of California San Francisco +[20] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity of AthensWeill Medical College of Cornell University +[8] 
Active IndicationsCastration-Sensitive Prostate NeoplasmsHormone-Sensitive Prostate NeoplasmsHepatic Insufficiency +[8] 
Inactive IndicationsPeritoneal Neoplasms

Other Information

ATC CodeL02BB05
Related LinksWikipediaDrugBankKEGG